Zura Bio Ltd (NASDAQ: ZURA) is a clinical-stage biopharmaceutical company that develops in-licensed drug candidates, referred to in its filings as the ZB Assets, with no products approved for commercial sale as of its 10-K filed March 19, 2026. The company generates no product revenue. It funds operations through capital raises and has incurred significant operating losses since inception in January 2022. Zura Bio went public via a business combination with JATT Acquisition Corp, a Cayman Islands SPAC, which closed on March 20, 2023. The company is incorporated under the laws of England and Wales and lists on the Nasdaq Capital Market. As of the filing date, Zura Bio had not completed any late-stage clinical trials and relies on third-party contract research organizations to conduct preclinical and clinical work. A cell line license agreement with WuXi Biologics, entered July 2023, included a $150,000 non-refundable license fee and provides for royalty payments on future net sales if commercial manufacturing is conducted outside WuXi Biologics.

Revenue model

No product revenue as of the 10-K filed March 19, 2026. The company is pre-commercial and funds operations through capital raises. Future revenue, if any, would depend on obtaining regulatory approval and commercializing drug candidates, or monetizing assets through licensing or sales.

Products and services

In-licensed drug candidates referred to as the ZB Assets. No products are approved for commercial sale as of the filing date. The company holds a cell line license from WuXi Biologics covering certain know-how, cell lines, and biological materials for manufacturing licensed products.

Customers and end markets

No commercial customers as of the filing date. Target end markets are not specified in the filing excerpts provided.

Value-chain role

Clinical-stage drug developer. Relies on third-party contract research organizations for preclinical and clinical trial execution. Licenses cell line technology from WuXi Biologics for potential future manufacturing.

Geographic exposure

Incorporated in England and Wales. Listed on the Nasdaq Capital Market. Data privacy considerations reference the EEA, UK, and United States, indicating some operational presence or data flows across those jurisdictions.

Source: SEC 10-K, filed 2026-03-19

Industry: Biological Products, (No Diagnostic Substances) Peers: Achieve Life Sciences Inc Acumen Pharmaceuticals Inc Alaunos Therapeutics Inc Jasper Therapeutics Inc C4 Therapeutics, Inc G1 Therapeutics, Inc. Greenwich Lifesciences Inc Ocugen Inc INmune Bio Inc